EDX Medical Group (LSE:EDX) has kept up a steady flow of announcements in November 2026. On 10 November the company said that a breast cancer prognostic test developed by Caris Life Sciences was now available in the UK through EDX, the latest in a series of service launches that also includes employee health screening, bowel cancer testing and a rapid pneumonia test. A day later it announced the appointment of directors, following the arrival of a new chair at the end of October.
What the company does
EDX Medical is a diagnostics Business with a portfolio of testing services covering cancer, infectious disease and wider health screening. Its announcements during 2026 describe a model built on partnerships, supplying tests developed in-house or by third parties to the NHS, private healthcare providers and employers.
Latest developments
The breast cancer test, Caris MI Clarity, is an AI-based prognostic tool that estimates the risk of distant recurrence over both the short term, up to five years, and the longer term, from five to 15 years. It is intended to sort patients into low or high-risk groups at initial diagnosis, and EDX said it had been validated in Clinical Trials involving tens of thousands of participants. EDX is supplying it in the UK under an agreement with Caris. No financial figures were given.
Earlier in the year EDX announced a service agreement with Astron Health in July, the launch of an employee health screening service the same month, and the full launch of its BC95 bowel cancer testing service on 21 July. In August it said a rapid pneumonia test had been deployed for NHS patients and provided an update on the Scottish Prostate Cancer Initiative. On 17 September it announced an employee health contract with the Arnold Clark Group.
On 30 October 2026 the company appointed Professor Michael John Owen as non-executive chairman, succeeding Jason Holt with immediate effect. Professor Owen co-founded Kymab and previously held senior roles at GlaxoSmithKline.
Financial and Dividend picture
In August 2026 EDX raised approximately £2.7 million through a share subscription at 14 pence per share, with warrants attached. The proceeds were earmarked for expanding the employee health screening service, which combines biomarker testing with follow-up diagnostics. At the time the company said definitive contracts were in progress with three significant UK employers, with testing expected to begin in the fourth quarter of 2026. It also disclosed that about £860,000 of Revenue invoiced in the year to 31 March 2026 had been deferred into the current financial year. Following the fundraise, the company had 431,373,146 ordinary shares in issue. No dividend has been announced, which is typical for an early-stage diagnostics group.
Sector and index context
EDX is one of a number of small diagnostics and healthcare services companies in the FTSE AIM All Share Index. The segment is marked by frequent share issues and partnerships whose value can take time to reach reported revenue.
Key risks
The business remains reliant on external funding, and further share issues could dilute existing holders. Revenue recognition timing, as illustrated by the deferred sum, can make results uneven. Commercial uptake of newly launched tests and employer screening contracts is not yet proven at scale, and reliance on third-party test developers carries Partnership risk.
What to watch next
Key milestones include the start of testing under the employer contracts in the fourth quarter, any disclosed revenue from the Caris test, and interim results for the six months to September 2026. The reshaped board under the new chair will also be watched for any change in strategy.






Please wait processing your request...